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Background: Excess peroxisome proliferator-activated receptor (PPAR) stimulation has been associated with
detrimental health effects including impaired myocardial function. Recently, supplementation with n-3 polyunsaturated
fatty acids (PUFA) has been associated with improved left ventricular function and functional capacity in patients with
dilated cardiomyopathy. We investigated the long-term effects of the pan-PPAR agonist tetradecylthioacetic acid (TTA)
and/or high-dose fish oil (FO) on cardiac fatty acid (FA) composition and lipid metabolism. Male Wistar rats were given
one out of four different 25% (w/v) fat diets: control diet; TTA diet; FO diet; or diet containing both TTA and FO.
Results: After 50 weeks n-3 PUFA levels were increased by TTA and FO in the heart, whereas liver levels were reduced
following TTA administration. TTA was associated with a decrease in arachidonic acid, increased activities of carnitine
palmitoyltransferase II, fatty acyl-CoA oxidase, glycerol-3-phosphate acyltransferase, and fatty acid synthase in the heart.
Furthermore, cardiac Ucp3 and Cact mRNA was upregulated.
Conclusions: Long-term treatment with the pan-PPAR agonist TTA or high-dose FO induced marked changes in PUFA
composition and enzymatic activity involved in FA metabolism in the heart, different from liver. Changes included
increased FA oxidation and a selective increase in cardiac n-3 PUFA.
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Tetradecylthioacetic acidBackground
Peroxisome proliferator-activated receptors (PPAR) are
members of the nuclear hormone receptor family con-
sisting of three subtypes (α, δ, and γ) with distinct and
overlapping expression patterns [1]. PPARα seems to
be the primary transcription regulator of enzymes
involved in fatty acid (FA) oxidation in the heart. A
substrate switch from FA to glucose is thought to be a
result of decreased PPARα activity [2]. The healthy
heart generates most of its energy as ATP through FA
catabolism, which primarily occurs in mitochondria,* Correspondence: Elin.Strand@med.uib.no
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reproduction in any medium, provided the orbut also to a small extent in peroxisomes [3]. Thus, a
continuous FA supply to the heart is important to sus-
tain the contractile activity as this tissue can store and
synthesize FA only to a limited extent [4]. Excess
PPARα stimulation may, however, have detrimental
effects [5] including substrate overload of FA in the
tissue, which is also associated with conditions like
obesity and insulin resistance [6]. Myocardial dysfunction
could hereby be the result of an obesity-associated
reduced glucose and increased FA utilization in heart
[7,8]. Lipotoxicity affects mitochondrial function through
altered protein phosphorylation and increased levels of
cytotoxic intermediate products of β-oxidation, which
could lead to mitophagy (controlled degradation of mito-
chondria) or apoptosis [9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eicosapentaenoic acid (EPA, C20:5n-3) and docosahexae-
noic acid (DHA, C22:6n-3), has been associated with
reduced triacylglycerol (TAG) levels, anti-inflammatory
effects, and a lowered risk of cardiovascular disease and
mortality [10,11]. These beneficial effects may be less evi-
dent in patients with stable angina [12,13], but particu-
larly pronounced in patients with reduced ventricular
function and heart failure [14]. Very high doses of n-3
PUFA could, however, be pro-inflammatory and pro-
oxidative [15].
Fibrates are a group of specific PPARα-targeted drugs
being utilized during the past three decades due to their
TAG-reducing effects. Their clinical gain, however, still
remains to be demonstrated [16,17], and their routine
use in combined hyperlipidemia has recently been aban-
doned [18]. Thus, excess PPARα activation may be asso-
ciated with unfavorable metabolic effects that could
counteract the apparent beneficial effects on lipid me-
tabolism and inflammation.
Similarly to PUFA and fibrates, tetradecylthioacetic acid
(TTA) has an especially pronounced affinity to PPARα
[19]. TTA is a saturated FA analogue with 16 carbon
atoms and one sulphur atom at position three, belonging
to a group of sulphur-substituted FA (3-thia FA) with
pan-PPAR activation properties [20]. It is known to re-
duce plasma TAG, probably due to hepatic proliferation
of mitochondria and an increased β-oxidation of FA
through PPAR-dependent mechanisms [21].
To this date inconsistent results from only a limited
number of previous studies on the effects of PPARα ago-
nists on cardiac substrate metabolism exist [22-27]. We
hypothesized that treatment with the pan-PPAR agonist
TTA and/or high-dose FO, would influence cardiac lipid
metabolism and thereby affect FA composition. Data
from liver was also applied to reveal organ specific
changes in the heart.Results
Animal body weight and cardiac lipids
Mean (±SD) weight of the animals at study start was 266
(±32) g, and there were no significant weight differences
between groups. During the study animals receiving
TTA or the combination of TTA and FO had signifi-
cantly reduced body weight gains compared to control
(p < 0.001 for both groups). In addition, all groups had
an average comparable feed intake [28]. To eliminate the
possibility of an effect-modification caused by the
jejuno-gastric reflux surgical procedure, changes in body
weight and plasma lipids were studied in an 11 week
pilot study. This study did not reveal any statistically sig-
nificant differences in neither body weight nor plasma
lipids when comparing operated animals to controls.After 50 weeks of dietary intervention there was no
change in cardiac TAG as a result of TTA or FO treat-
ment. There was, however, a significant increase in total
cholesterol after TTA (mean± SD, 3.21 ± 0.20 vs.
2.93 ± 0.24 μmol/g heart tissue, p < 0.001), and in phos-
pholipids after FO (14.68 ± 0.91 vs. 13.69 ± 0.88 μmol/g
heart tissue, p < 0.001) treatment.Changes in cardiac fatty acids following TTA and/or FO
administration
Two-way ANOVA indicated a significant increase in
total FA (p = 0.002) in the heart of animals receiving
TTA (Table 1). Total saturated FA (SFA) were decreased
following TTA treatment (p < 0.001; Figure 1), while
monounsaturated FA (MUFA) were decreased following
FO treatment (p = 0.001; Table 1). The interaction
(TTA*FO) for SFA was borderline significant in heart
(p = 0.01). The level of mead acid (MA, C20:3n-9) was
elevated following TTA treatment (p < 0.001) and
decreased in animals receiving FO (p < 0.001; Table 1).
Total cardiac n-6 PUFA were decreased after both
TTA and FO treatment (p < 0.001 for both; Figure 2a).
The decrease in total n-6 PUFA after TTA treatment
seemed to be due to a decrease in arachidonic acid
(ARA) levels (p < 0.001; Figure 2b), while most other
measured n-6 PUFA were increased (Additional file 1).
The interaction (TTA*FO) was significant for total n-6
PUFA (p = 0.003) and borderline significant for ARA
(p = 0.02).
There was a concomitant enrichment of total n-3
PUFA after TTA and FO treatment (p < 0.001 for both;
Figure 3a). The total increase in n-3 PUFA after TTA
administration was caused by significantly increased
levels of EPA (Figure 3b), docosapentaenoic acid (n-3)
(DPAn-3) (Figure 3c), and DHA (Figure 3d) (p < 0.001
for all), where DPAn-3 accounted for the foremost in-
crease. After FO treatment, on the other hand, DPAn-3
levels decreased (p < 0.001), while EPA and DHA
increased (<0.001 for both). The interaction (TTA*FO)
was significant for total n-3 PUFA, EPA, DPAn-3, and
DHA in heart (p < 0.001 for all). Total PUFA compos-
ition is provided as a supplementary table (Additional
file 1).
As expected, the n-3/n-6 PUFA ratio was greatly
increased following FO supplementation (p < 0.001).
However, this ratio was also significantly increased after
TTA treatment (p < 0.001; Table 1).
Desaturase activities were calculated as ratios of FA,
which represent indirect activity indexes. TTA treatment
led to a marked decrease in n-6 (p < 0.001) and an in-
crease in n-3 (p < 0.001) Δ5 desaturase indexes. There
was a concomitant increase in n-6 (p < 0.001) and
decrease in n-3 (p < 0.001) Δ6 desaturase indexes.
Table 1 Fatty acid composition (wt%) in heart of rats after 50 weeks of diet administration
Dietary supplementationa Statistical significance of variance
ratio (P)b, effects of
Control TTA FO TTA + FO TTA FO TTA*FO
Total FA (μg/g tissue) 22196 ± 2706c 24087 ± 1394 22578 ± 1503 24185 ± 1613 0.002 0.66 0.79
C16:0 11.1 ± 1.3 11.0 ± 1.1 10.0 ± 1.2 10.8 ± 0.6 0.25 0.05 0.22
C18:0 19.7 ± 1.2 18.8 ± 1.1 19.8 ± 1.1 18.9 ± 0.9 0.005 0.55 1.00
MUFA 10.2 ± 3.6 11.2 ± 3.1 8.4 ± 3.0 6.7 ± 2.6 0.70 0.001 0.14
C16:1n-7 0.24 ± 0.11 0.32 ± 0.11 0.21 ± 0.10 0.16 ± 0.09 0.70 0.002 0.03
C18:1n-7 2.6 ± 0.1 1.8 ± 0.2 2.4 ± 0.2 2.1 ± 0.2 <0.001 0.79 <0.001
C16:1n-9 0.10 ± 0.05 0.15 ± 0.04 0.11 ± 0.06 0.10 ± 0.04 0.27 0.13 0.09
C18:1n-9 (OA) 6.9 ± 3.4 8.5 ± 2.9 5.2 ± 2.7 3.9 ± 2.3 0.85 <0.001 0.08
C20:3n-9 (MA) 0.10 ± 0.01 0.55 ± 0.28 0.06 ± 0.01 0.05 ± 0.01 <0.001 <0.001 <0.001
C18:2n-6 (LA) 15.7 ± 1.0 17.2 ± 2.0 9.2 ± 1.0 5.8 ± 1.2 0.03 <0.001 <0.001
C18:3n-3 (ALA) 0.15 ± 0.06 0.20 ± 0.06 0.14 ± 0.06 0.10 ± 0.06 0.57 0.004 0.02
C18:4n-3 0.4 ± 0.3k 0.3 ± 0.3k 82.8 ± 38.0k 89.4 ± 30.4k 0.64 <0.001 0.64
TTA ND 2.8 ± 1.0 ND 1.7 ± 0.5
TTA:1n-8 ND 0.79 ± 0.49 ND 0.12 ± 0.04
n-3 PUFA/n-6 PUFA ratio 0.39 ± 0.04 0.55 ± 0.13 1.6 ± 0.2 3.9 ± 1.1 <0.001 <0.001 <0.001
Δ5 desaturase index (n-6)d 49.0 ± 4.6 9.8 ± 1.8 38.5 ± 5.8 10.6 ± 1.5 <0.001 <0.001 <0.001
Δ5 desaturase index (n-3)e 2.6 ± 0.4 4.2 ± 0.7 24.5 ± 4.3 36.4 ± 7.0 <0.001 <0.001 <0.001
Δ6 desaturase index (n-6)f 1.1 ± 0.4k 2.6 ± 0.7k 2.5 ± 0.7k 7.9 ± 2.0k <0.001 <0.001 <0.001
Δ6 desaturase index (n-3)g 2.7 ± 2.3k 1.7 ± 1.4k 0.61 ± 0.10 0.94 ± 0.19 <0.001 <0.001 <0.001
Δ9 desaturase index (C16)h 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.73 0.001 0.003
Δ9 desaturase index (C18)i 0.36 ± 0.22 0.46 ± 0.18 0.27 ± 0.16 0.21 ± 0.14 0.71 0.001 0.13
Anti-inflammatory indexj 68.8 ± 6.7 155 ± 37.6 274 ± 50.1 866 ± 234 <0.001 <0.001 <0.001
Abbreviations: TTA, tetradecylthioacetic acid; FO, fish oil; FA, fatty acids; MUFA, monounsaturated fatty acids; OA, oleic acid; MA, mead acid; LA, linoleic acid; ALA,
α-linolenic acid; PUFA, polyunsaturated fatty acids; ND, not detectable.
a n=12 in each group.
b P-values from two-way ANOVA.
c Values are mean ± SD.
d C20:4n-6/C20:3n-6 (an indirect index of Δ5 desaturase activity based on n-6 PUFA).
e C20:5n-3/C20:4n-3 (an indirect index of Δ5 desaturase activity based on n-3 PUFA).
f C18:3n-6/C18:2n-6 (an indirect index of Δ6 desaturase activity based on n-6 PUFA).
g C18:4n-3/C18:3n-3 (an indirect index of Δ6 desaturase activity based on n-3 PUFA).
h C16:1n-7/C16:0 (an indirect index of Δ9 desaturase activity based on C16 SFA/MUFA).
i C18:1n-9/C18:0 (an indirect index of Δ9 desaturase activity based on C18 SFA/MUFA).
j ((C22:6n-3 + C22:5n-3 + C20:3n-6 + C20:5n-3)/C20:4n-6)*100.
k Values are *10-3.
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for both supplements (p < 0.001; Table 1).Changes in liver fatty acids following TTA and/or FO
administration
As the liver is of crucial importance for FA metabolism,
liver composition was also included for comparison
(Table 2). There was a significant increase in C16:0 and
a decrease in C18:0 levels in liver after dietary interven-
tion with TTA (p < 0.001 for both), while FO decreased
total SFA (p < 0.001). Total MUFA were increased after
TTA and decreased following FO treatment (p < 0.001
for both). As in heart muscle, liver MA was elevatedfollowing TTA treatment and decreased in animals re-
ceiving FO (p < 0.001 for both).
Total liver n-6 PUFA were decreased after TTA and
FO administration (p < 0.001, Figure 2a). Furthermore,
n-3 PUFA were increased after FO (p < 0.001) but
decreased after TTA (p < 0.001) treatment (Figure 3a).
This decrease in n-3 PUFA in liver after TTA treatment
was the opposite of what was seen in heart muscle
(Figure 3a). The interaction (TTA*FO) was significant
for n-6 PUFA (p = 0.004), n-3 PUFA (p = 0.004), EPA
(p < 0.001), and DPAn-3 (p = 0.001).
Main changes in estimated desaturase indexes in liver
were similar to changes in heart, except from an increase
in Δ9 desaturase activity (C18 ratio) after TTA
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Figure 1 Saturated fatty acids (SFA) (wt%) in heart and liver.
Levels of SFA in heart (dark grey bars) and liver (light grey bars) and
distribution in diet groups were as indicated. Values are mean± SD.
Asterix indicates statistical significance of variance ratio and effects
of TTA (long clamps) and FO (short clamps) (*p < 0.05; ***p < 0.001).
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inflammatory index remained unchanged after TTA
treatment.0
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Figure 2 n-6 polyunsaturated fatty acids (PUFA) (wt%) in heart
and liver. Levels of n-6 PUFA (a) and arachidonic acid (b) in heart
(dark grey bars) and liver (light grey bars) and distribution in diet
groups were as indicated. Values are mean± SD. Asterix indicates
statistical significance of variance ratio and effects of TTA (long
clamps) and FO (short clamps) (***p < 0.001).Changes in the activities of key metabolic enzymes
TTA treatment was associated with reduced activity of
carnitine palmitoyltransferase (CPT)-I in the heart
(p < 0.001; Table 3), but the effect was less pronounced
in the presence of malonyl-CoA (the natural inhibitor of
CPT-I) (p < 0.001). The activity of CPT-II was increased
after TTA treatment (p < 0.001; Table 3). FO treatment
did not affect the activities of CPT-I or CPT-II.
Enzyme activities of fatty acyl-CoA oxidase (ACOX) and
glycerol-3-phosphate acyltransferase (GPAT) in heart tis-
sue were induced by TTA and FO (p< 0.001 for all), while
fatty acid synthase (FAS) was induced by TTA (p< 0.001).
PPAR-targeted genes and cardiac expression at the mRNA
level
A total of 16 different PPAR-targeted genes were selected
and gene expression was measured with real-time PCR
(qPCR) on total RNA isolated from heart tissue. Cpt-Ib
(isoform of Cpt-I expressed in muscle) was one out of
three genes that showed enhanced expression at the
mRNA level after TTA administration (p = 0.003; Table 4).
It was also induced by FO (p = 0.003). Also Cact mRNA,
encoding the protein carnitine-acylcarnitine translocase,
was upregulated after TTA treatment (p = 0.002). The
Ucp3 gene (encoding the uncoupling protein 3) was
upregulated (p < 0.001), while Ucp2 (p = 0.008), Pparδ
(p = 0.002), and Pparγ (p < 0.001) were decreased after
TTA administration. Fatp1 (encoding FA transport
protein 1, involved in myocardial FA uptake) showed
increased expression after FO supplementation
(p = 0.001). There was no change in mRNA levels of
PPARα following treatment with any supplement.Discussion
Long-term treatment with the pan-PPAR agonist TTA
or high-dose FO induced marked changes in PUFA com-
position in heart muscle, resulting in decreased n-6
PUFA and increased n-3 PUFA. The significantly
increased levels of EPA, DPAn-3, and DHA in the heart
following TTA treatment was the opposite of what has
previously been seen in plasma [29] and as shown in
liver. The activity of enzymes involved in FA metabolism
were also changed in the heart after TTA treatment, in-
cluding increased CPT-II, ACOX, GPAT, and FAS activ-
ities as well as a significant upregulation of Ucp3 and
Cact at the mRNA level.
There was no change in expression of Cd36, Fabp3, or
Fatp1 mRNA, nor a change in TAG concentration, which
gives no indication of enhanced entry of FA into the
heart. Moreover, as TTA is reported to decrease the n-3
PUFA content in very low density lipoprotein (VLDL)
particles [30], a selective increased secretion of n-3 PUFA
from liver to plasma is unlikely. Dietary n-3 PUFA has
been shown to decrease ARA in rat cardiac mitochondrial
phospholipids [31], which is in accordance with the
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Figure 3 n-3 polyunsaturated fatty acids (PUFA) (wt%) in heart and liver. Levels of n-3 PUFA (a), eicosapentaenoic acid (EPA) (b),
docosapentaenoic acid n-3 (DPAn-3) (c), and docosahexaenoic acid (DHA) (d) in heart (dark grey bars) and liver (light grey bars) and distribution
in diet groups were as indicated. Values are mean± SD. Asterix indicates statistical significance of variance ratio and effects of TTA (long clamps)
and FO (short clamps) (***p < 0.001).
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PUFA in heart, TTA led to a specific decrease in ARA
and at the same time an increase in most other n-6
PUFA. Both TTA and FO induced an increase in cardiac
EPA and DHA. However, the increase in total n-3 PUFA
as a TTA effect was particularly evident for DPAn-3,
while cardiac DPAn-3 was decreased after FO treatment.
Based on a previous study in platelets, ARA was shunted
to the lipoxygenase pathway in the presence of DPAn-3
[32]. Thus, an apparent link exists between ARA and
DPAn-3, which might explain part of the mechanisms
which underlie decreased ARA and increased DPAn-3 as
exerted by TTA. These TTA effects were specific for
heart muscle. Similarly, the PPARα-agonist clofibrate has
previously been demonstrated to have profound effects
on myocardial FA composition, including reduced ARA
and increased DHA [26].
TTA induces proliferation of mitochondria and per-
oxisomes in the liver [33]. Although there were no
changes in the gene expression of Pgc1α, Tfam or Nrf1
in heart after TTA administration, a significant increase
in activity of CPT-II and gene expression of Cpt-Ib and
Cact was observed. Furthermore, the peroxisomal
β-oxidation system seemed to be induced as the ACOX
activity was significantly increased both after TTA and
FO administration. These findings suggest that TTA
induces both mitochondrial and peroxisomal β-oxidation
in heart, supported by two previous studies demonstrat-
ing increased myocardial FA oxidation by TTAtreatment, associated with reduced cardiac efficiency
[22,27]. It has also been shown that TTA induces both
CPT-II and ACOX in liver, and to an even larger extent
compared to what we report in heart [28]. TTA treat-
ment also resulted in increased activities of cardiac
GPAT and FAS. There was also increased enzyme activity
of GPAT after FO treatment. This enzyme catalyzes the
synthesis of lysophosphatidic acid from glycerol-3-
phosphate and long-chain acyl-CoA [34]. Thus, the por-
tion of activated acyl-CoA that is not used for mitochon-
drial β-oxidation will be esterified into TAG and other
glycerolipids, including phospholipids. The increased
lipogenesis and TAG biosynthesis together with stimu-
lated FA catabolism can thus explain the enrichment of
n-3 PUFA in the heart both after TTA and FO treatment.
n-3 PUFA, which are poorly oxidizable FA substrates
compared to SFA [35], will most likely be diverted to-
wards phospholipid synthesis and not β-oxidation. This
could render n-3 PUFA less available for further metab-
olism. Altogether, an increased incorporation of n-3
PUFA into phospholipids in heart and a probably
increased metabolism of n-3 PUFA in liver due to an ex-
tensive increase in CPT-II and ACOX [28] could explain
why n-3 PUFA levels increase in heart and decrease in
liver and plasma following TTA treatment. Together with
the previously mentioned unfavorable metabolic effects
of excess PPAR activation [5,22], we consider the possi-
bility that the observed increase of cardiac n-3 PUFA in
the current study might not be solely beneficial.
Table 2 Fatty acid composition (wt%) in liver of rats after 50 weeks of diet administration
Dietary supplementationa Statistical significance of
variance ratio (P)b, effects of
Control TTA FO TTA + FO TTA FO TTA*FO
Total FA (μg/g tissue) 42287 ± 4330c 39177 ± 2734 43285 ± 4935 41488 ± 4163 0.10 0.27 0.66
C16:0 18.8 ± 0.7 19.8 ± 1.2 16.9 ± 0.6 19.5 ± 0.7 <0.001 0.001 0.01
C18:0 16.1 ± 1.2 14.1 ± 1.0 16.0 ± 0.8 13.3 ± 1.2 <0.001 0.22 0.38
MUFA 17.8 ± 2.2 22.4 ± 3.1 12.4 ± 1.5 17.0 ± 1.6 <0.001 <0.001 0.99
C16:1n-7 0.61 ± 0.38 0.69 ± 0.30 0.37 ± 0.11 0.40 ± 0.08 0.52 0.007 0.76
C18:1n-7 1.7 ± 0.3 1.4 ± 0.1 1.2 ± 0.1 1.1 ± 0.0 <0.001 <0.001 0.09
C16:1n-9 0.20 ± 0.06 0.41 ± 0.07 0.20 ± 0.03 0.37 ± 0.08 <0.001 0.45 0.33
C18:1n-9 (OA) 14.7 ± 1.8 19.5 ± 2.9 10.0 ± 1.4 14.7 ± 1.6 <0.001 <0.001 0.95
C20:3n-9 (MA) 0.23 ± 0.02 1.15 ± 0.45 0.10 ± 0.01 0.15 ± 0.03 <0.001 <0.001 <0.001
C18:2n-6 (LA) 15.5 ± 1.3 9.3 ± 2.0 11.9 ± 0.6 11.7 ± 0.7 <0.001 0.19 <0.001
C18:3n-3 (ALA) 0.35 ± 0.06 0.08 ± 0.03 0.34 ± 0.06 0.17 ± 0.03 <0.001 0.03 0.006
C18:4n-3 0.02 ± 0.00 0.01 ± 0.00 0.12 ± 0.03 0.07 ± 0.01 <0.001 <0.001 0.002
TTA ND 1.8 ± 0.4 ND 1.3 ± 1.1
TTA:1n-8 ND 0.97 ± 0.18 ND 0.56 ± 0.17
n-3 PUFA/n-6 PUFA ratio 0.18 ± 0.02 0.16 ± 0.04 1.20 ± 0.18 1.02 ± 0.13 0.02 <0.001 0.05
Δ5 desaturase index (n-6)d 29.6 ± 8.1 11.8 ± 2.1 24.5 ± 5.2 7.8 ± 1.1 <0.001 0.02 0.77
Δ5 desaturase index (n-3)e 3.6 ± 0.6 3.4 ± 0.9 34.9 ± 5.1 35.5 ± 6.3 0.91 <0.001 0.78
Δ6 desaturase index (n-6)f 14.0 ± 3.2k 47.9 ± 14.9k 4.4 ± 1.2k 16.9 ± 2.8k <0.001 <0.001 0.001
Δ6 desaturase index (n-3)g 18.1 ± 3.9 9.8 ± 3.5 3.0 ± 0.5 2.5 ± 0.3 <0.001 <0.001 <0.001
Δ9 desaturase index (C16)h 0.03 ± 0.02 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.00 0.92 0.01 0.66
Δ9 desaturase index (C18)i 0.92 ± 0.17 1.40 ± 0.29 0.63 ± 0.11 1.12 ± 0.24 <0.001 0.001 0.90
Anti-inflammatory indexj 34.0 ± 2.8 32.7 ± 7.5 254 ± 53.5 253 ± 47.1 0.91 <0.001 0.99
Abbreviations: TTA, tetradecylthioacetic acid; FO, fish oil; FA, fatty acids; MUFA, monounsaturated fatty acids; OA, oleic acid; MA, mead acid; LA, linoleic acid; ALA,
α-linolenic acid; PUFA, polyunsaturated fatty acids; ND, not detectable.
a n=8 in each group.
b P-values from two-way ANOVA.
c Values are mean ± SD.
d C20:4n-6/C20:3n-6 (an indirect index of Δ5 desaturase activity based on n-6 PUFA).
e C20:5n-3/C20:4n-3 (an indirect index of Δ5 desaturase activity based on n-3 PUFA).
f C18:3n-6/C18:2n-6 (an indirect index of Δ6 desaturase activity based on n-6 PUFA).
g C18:4n-3/C18:3n-3 (an indirect index of Δ6 desaturase activity based on n-3 PUFA).
h C16:1n-7/C16:0 (an indirect index of Δ9 desaturase activity based on C16 SFA/MUFA).
i C18:1n-9/C18:0 (an indirect index of Δ9 desaturase activity based on C18 SFA/MUFA).
j ((C22:6n-3 + C22:5n-3 + C20:3n-6 + C20:5n-3)/C20:4n-6)*100.
k Values are *10-3.
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time an increased CPT-II activity in heart, which is in
accordance with earlier results on TTA administration
in liver [36]. Although CPT-I has been assumed to be
rate-limiting for FA oxidation in all tissues, a study has
shown that about 50% of CPT-I activity can be inhibited
before affecting the actual flux of β-oxidation in the heart
[37]. In addition, the present study showed that TTA
affected CPT-I activity in the presence of malonyl-CoA
by decreasing the sensitivity against this natural inhibitor
of CPT-I [38]. However, the reduced CPT-I activity
could contribute to an inadequate transport or oxida-
tion of long-chain FA in heart, while shorter FA that donot depend on CPT-I are completely oxidized in the
mitochondria.
Expression of uncoupling protein Ucp3 mRNA is
upregulated by PPAR activation, which is consistent with
our current findings in the heart, with a strong signifi-
cant increase after TTA and borderline significant in-
crease after FO administration. This may lead to an
increased FA transport and β-oxidation. Although its
exact function remains largely unknown, UCP3 could
act as an antioxidant and increased Ucp3 mRNA expres-
sion might be a response to an increase in oxidative
stress [39]. A previous study associated increased cardiac
levels of UCP3 to decreased efficiency in rat heart after
Table 3 Enzyme activity (nmol/min/mg protein) in heart of rats after 50 weeks of diet administration
Dietary supplementationa Statistical significance of
variance ratio (P)b, effects of
Control TTA FO TTA + FO TTA FO TTA*FO
CPT-I 2.79 ± 0.26c 1.69 ± 0.38 2.54 ± 0.12 1.75 ± 0.14 <0.001 0.22 0.06
CPT-I (with malonyl-CoA) 1.89 ± 0.21 1.23 ± 0.28 1.77 ± 0.14 1.31 ± 0.13 <0.001 0.73 0.14
CPT-II 10.79 ± 1.03 23.55 ± 3.15 12.40 ± 2.33 22.39 ± 4.32 <0.001 0.82 0.15
ACOX 1.65 ± 0.31 4.53 ± 1.16 4.61 ± 1.41 8.47 ± 1.37 <0.001 <0.001 0.19
GPAT 0.25 ± 0.06 0.43 ± 0.09 0.39 ± 0.09 0.64 ± 0.14 <0.001 <0.001 0.37
FAS 0.04 ± 0.01 0.09 ± 0.01 0.06 ± 0.02 0.10 ± 0.02 <0.001 0.01 0.34
Abbreviations: TTA, tetradecylthioacetic acid; FO, fish oil; CPT-I, carnitine palmitoyltransferase I; CPT-II, carnitine palmitoyltransferase II; ACOX, fatty acyl-CoA
oxidase; GPAT, glycerol-3-phosphate acyltransferase; FAS, fatty acid synthase.
a n=10 in each group.
b P-values from two-way ANOVA.
c Values are mean ± SD.
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drial uncoupling [40].
The marked changes on FA metabolism induced by
TTA could possibly result in essential FA deficiency due
to the decreased levels of n-3 PUFA in liver and plasma
[28]. In support of this, TTA treatment was associated
with elevated levels of MA both in heart and liver [41].
A metabolic switch inducing the conversion of MATable 4 Gene expression of selected genes in heart of rats af
Dietary supplementation
Control TTA FO
Cpt-Ib 1.00 ± 0.17d 1.29 ± 0.17 1.29 ± 0.19
Ucp2 1.00 ± 0.17 0.92 ± 0.29 1.04 ± 0.17
Ucp3 1.00 ± 0.43 2.08 ± 0.76 1.74 ± 0.50
Pgc1α 1.00 ± 0.10 0.99 ± 0.16 1.04 ± 0.19
Tfam 1.00 ± 0.08 0.99 ± 0.10 0.98 ± 0.11
Nrf1 1.00 ± 0.14 1.06 ± 0.11 1.21 ± 0.12
Cd36 1.00 ± 0.14 0.94 ± 0.13 1.09 ± 0.24
Cact 1.00 ± 0.14 1.26 ± 0.30 1.18 ± 0.17
Fabp3 1.00 ± 0.10 1.15 ± 0.37 1.23 ± 0.17
Acads 1.00 ± 1.14 2.31 ± 1.69 1.92 ± 1.91
Acadm 1.00 ± 0.18 1.15 ± 0.28 1.14 ± 0.28
Acadvl 1.00 ± 0.15 1.12 ± 0.20 1.14 ± 0.16
Pparα 1.00 ± 0.34 0.88 ± 0.14 1.15 ± 0.33
Pparδ 1.00 ± 0.18 0.87 ± 0.09 1.12 ± 0.17
Pparγ 1.00 ± 0.28 0.83 ± 0.16 1.33 ± 0.34
Fatp1 1.00 ± 0.28 1.25 ± 0.25 1.55 ± 0.53
Abbreviations: TTA, tetradecylthioacetic acid; FO, fish oil; Cpt-Ib, carnitine palmitoylt
peroxisome proliferative activated receptor (gamma coactivator 1); Tfam, transcripti
differentiation 36; Cact, carnitine-acylcarnitine translocase; Fabp3, fatty acid binding
dehydrogenase medium chain; Acadvl, acyl-CoA dehydrogenase very long chain; Pp
proliferator-activated receptor d; Pparγ, peroxisome proliferator-activated receptor γ
a Relative to control diet.
b n=10 in each group.
c P-values from two-way ANOVA.
d Values are mean ± SD.occurs as a result of low dietary levels of linoleic acid
(LA) and α-linolenic acid (ALA). Such signs of essential
FA deficiency have been reported in animals on a par-
tially hydrogenated FO diet [42] or after treatment with
fenofibrate [43], and may be caused by excess PPAR acti-
vation. Even though there was no change in PPARα
mRNA after treatment with TTA or FO, we assume that
the effects were primarily due to activation of PPARα.ter 50 weeks of diet administrationa
b Statistical significance of
variance ratio (P)c, effects of
TTA + FO TTA FO TTA*FO
1.34 ± 0.14 0.003 0.003 0.04
0.74 ± 0.18 0.008 0.29 0.11
2.31 ± 0.62 <0.001 0.01 0.18
1.05 ± 0.21 0.95 0.36 0.85
0.90 ± 0.15 0.23 0.11 0.33
0.98 ± 0.16 0.06 0.13 0.002
0.99 ± 0.10 0.14 0.20 0.68
1.37 ± 0.22 0.002 0.04 0.61
1.24 ± 0.14 0.26 0.03 0.32
0.83 ± 1.22 0.82 0.56 0.02
1.13 ± 0.26 0.43 0.45 0.32
1.05 ± 0.34 0.80 0.64 0.15
1.03 ± 0.20 0.16 0.09 0.97
0.90 ± 0.19 0.002 0.15 0.39
0.87 ± 0.17 <0.001 0.02 0.07
1.50 ± 0.31 0.39 0.001 0.19
ransferase Ib; Ucp2, uncoupling protein 2; Ucp3, uncoupling protein 3; Pgc1α,
on factor A mitochondrial; Nrf1, nuclear respiratory factor; Cd36, cluster of
protein 3; Acads, acyl-CoA dehydrogenase short chain; Acadm, acyl-CoA
arα, peroxisome proliferator-activated receptor α; Pparδ, peroxisome
; Fatp1, fatty acid transport protein 1.
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TTA [21] and FO [44] treatment have previously been
shown in rodent models.
A beneficial effect of n-3 PUFA supplementation has
recently been demonstrated in patients with reduced
ventricular function and heart failure [14]. Could the
observed TTA effects on n-3 PUFA distribution in liver
and heart tell us why n-3 PUFA supplements give favor-
able effects under certain conditions? There might be a
link from the n-3 PUFA levels in heart to the association
between TTA treatment and reduced cardiac efficiency
in normal but not in diabetic mice [22,27]. Furthermore,
FO shows some similar effects to TTA on cardiac me-
tabolism, perhaps through PPARα activating mechan-
isms, which might indicate detrimental effects by giving
high doses. However, PPAR independent effects of TTA
cannot be excluded. Whether the observed increase of
n-3 PUFA in the hearts of rats treated with TTA and FO
might also be related to PPAR effects in humans remain
to be shown. Additionally, the effect of TTA on PUFA
composition in the heart was directly associated with its
TTA concentration (data not shown). It is also notable
that PPARα and its agonists hold important properties
beyond FA and glucose metabolism, like effects on
amino acid metabolism [45]. These aspects open for
more extensive investigations of PPAR stimulation and
cardiac metabolism.
Conclusions
In summary, long-term administration of the pan-PPAR
agonist TTA or high-dose FO to rats, were associated
with distinct effects on lipid metabolism in the heart and
systemically. FA composition was changed, including a
selective increase in n-3 PUFA in rat heart muscle, indi-
cating a limited capacity of heart to metabolize the
poorly oxidizable n-3 PUFA compared to SFA. Further,
cardiac mitochondrial and peroxisomal FA oxidation
seemed to be increased, together with a possible
increased mitochondrial uncoupling after TTA treat-
ment. FO in high doses could give similar effects to
TTA in heart. These findings might altogether indicate a
reduction in cardiac efficiency and are relevant for fur-
ther studies on the effects of excess PPAR activation in
relation to myocardial dysfunction development.
Methods
Study design
The animal experiments were standardized according to
the Guidelines for the Care and Use of Experimental
Animals, and the protocol was approved by the Norwe-
gian State Board for Biological Experiments with Living
Animals.
Male Wistar rats, aged eight to ten weeks, were
obtained from Taconic Europe A/S (previouslyMöllegaard and Blomholtgaard, Ry, Denmark). They
were housed in groups of five and maintained at a con-
stant 12 h light–dark cycle at a temperature of 22 ± 1°C
and a relative humidity of 55 ± 5%. Animals were accli-
matized under these conditions for one week prior to
study start and had free access to standard chow during
the acclimation period and water at all times. During the
feeding period the animals received one out of the follow-
ing four diets for a period of 50 weeks: control diet with
25% (w/v) fat (23%w/v lard, 2%w/v soybean oil); diet
supplemented with TTA (0.375%w/v TTA, 22.6 w/v
lard, 2%w/v soybean oil); diet supplemented with FO
(10.4%w/v EPAX 4020 TG, 12.6%w/v lard, 2%w/v soy-
bean oil); or diet supplemented with TTA and FO
(0.375%w/v TTA, 10.4%w/v EPAX 4020 TG, 12.2 w/v
lard, 2%w/v soybean oil). These were complete diets
containing 20% (w/v) protein from casein from bovine
milk (Tine, Tolga, Norway). Lard (Ten Kate Vetten BV,
Musselkanaal, Netherlands) and soybean oil (Dyets Inc.,
Bethlehem, PA, USA) were used as fat sources. Other
ingredients were cornstarch, sucrose, fiber, AIN-93 G
mineral mix, AIN-93 vitamin mix, L-cysteine, choline
bitartrate (Dyets Inc.), and tert-butyl-hydroquinone
(Sigma-Aldrich). FO was provided by EPAX AS. TTA was
synthesized as previously described [46].
These animals were part of a larger study [47], where
they all underwent a jejuno-gastric reflux surgical pro-
cedure. A separate experiment enduring 11 weeks were
done comparing animals with and without operation, to
make sure that the procedure did not affect the nutri-
tional state in the animals. There was no difference in
body weight or plasma lipids between the two groups
(data not shown), and thus it can be assumed that the
operation had no adverse effects regarding nutrition.
Sampling protocol
The animals were sacrificed with isoflurane (Forene,
Abbott Laboratories, Abbott Park, IL) under non-fasting
conditions. The abdomen was opened in the midline
and blood was drawn by cardiac puncture and collected
in BD Vacutainer tubes containing EDTA (Becton,
Dickinson, and Company, Plymouth, UK). The heart and
liver tissues were collected and immediately freeze-
clamped as drainage of blood from the animal was
complete. Plasma and tissue samples were stored at
−80°C until analyses.
Quantification of lipids and fatty acids
Tissue samples were homogenized and lipids extracted
with chloroform-methanol [48]. Samples were evaporated
under nitrogen and redissolved in isopropanol before ana-
lysis. Lipids were measured on the Hitachi 917 system
(Roche Diagnostics, GmbH, Mannheim, Germany). Total
cholesterol (CHOD-PAP) and TAG (GPO-PAP) kits were
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DiaSys Diagnostic Systems GmbH (Holzheim, Germany).
FA methyl esters (FAME) were obtained by heating of
lipids with methanol at 90°C for one hour. Sulphuric acid
was used as a catalyst [49]. After extraction into an or-
ganic solvent, FAME were analyzed by gas–liquid chro-
matography (GC). The gas chromatograph (GC 8000
TOP, Finnigan, USA) was equipped with a programmed
temperature vaporization injector, flame-ionization de-
tector, AS 800 autosampler, and with a fused silica ca-
pillary column DB1-ms (J & W Scientific, USA).
Hydrogen was used as a carrier gas. Column temperature
was programmed from 110 to 310°C with a gradient of
2.5°C/min. GC signal was acquired and evaluated with
Chromeleon software (Dionex Corporation, USA). Peaks
were identified by means of known FA standards and by
means of mass spectra, obtained by GC/MS analysis
(GCQ, Finnigan, USA) on the same column. Internal
standard (C21:0) was used for quantification after calibra-
tion with known mixtures of FA standards. FA compos-
ition was presented as percentage by weight (wt%). The
anti-inflammatory index was calculated using the
formula: ((C22:6n-3+C22:5n-3 +C20:3n-6 +C20:5n-3)/
C20:4n-6)*100 [50].
Enzyme activities
Heart tissue samples were homogenized and fractionated
as previously described [23]. The activities of CPT-I and
-II [24], ACOX [51,52], GPAT [53], and FAS [54] were
measured in the post-nuclear extracts.
Gene expression analyses
Total cellular RNA was purified from heart tissue using
the RNeasy kit and the protocol for fibrous tissue (Qia-
gen GmbH, Hilden, Germany). RNA quantity was
determined spectrophotometrically (NanoDrop 1000,
NanoDrop products, Wilmington, DE, USA), while qual-
ity was evaluated by capillary electrophoresis (Agilent
2100 Bioanalyzer, Agilent Technologies Inc., Santa Clara,
CA, USA) prior to gene analyses. RNA was reversely
transcribed to cDNA in 100 μl reactions using TaqManW
Reverse Transcription Reagents (Applied Biosystems,
Foster City, CA, USA). Samples were treated with RNase
inhibitors as part of the protocol. Selected genes were
analyzed using qPCR. The qPCR was performed with
ABI PRISM 7900 HT Sequence Detection System (Ap-
plied Biosystems). The following 16 genes of interest
were selected: Rn00566242 (Cpt-Ib), Rn00571166
(Ucp2), Rn00565874 (Ucp3), Rn00580241 (Pgc1α),
Rn00580051_m1 (Tfam), Rn01455958_m1 (Nrf1),
Rn00580728 (Cd36), Rn00588652 (Cact), Rn00577366
(Fabp3), Rn00563649 (Acadvl), Rn00566390 (Acadm),
Rn00574634 (Acads), Rn00566193 (Pparα), Rn00565707
(Pparδ), Rn00440945 (Pparγ), and Rn00585821_m1(Fatp1). All primer/probe sequences for the genes studied
were obtained from Applied Biosystems. The MIQE
guidelines for qPCR analyses were used when selecting
house-keeping genes [55,56]. Out of the three house-
keeping genes originally included in the analyses:
Hs99999901_s1 (18 S, Eurogentec S.A., Seraing, Belgium),
Rn99999916_s1 (Gapdh, Applied Biosystems), and
Rn00821065_g1 (Arbp, Applied Biosystems), 18 S was
found to be the best using geNorm [57]. This endogenous
house-keeping gene was used to normalize the expression
value of each gene in all samples.
Statistical analyses
The results were presented as means with their standard
deviations (SD) for a minimum of eight and a maximum
of fifteen rats per group. Gene expression data was nor-
malized against the control diet group. Data was evalu-
ated by two-way ANOVA for treatment additivity and
synergy [58]. Results were not adjusted for multiple
comparisons, and thus p-values <0.01 were considered
significant. Statistics were performed by using PASW
Statistics for Windows, version 18 (SPSS Inc., Chicago,
IL, USA).
Additional file
Additional file 1: PUFA composition (wt%) in heart of rats after 50
weeks of diet administration.
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